Respiratory failure & ventilation
Intra-hospital transport of adult critically ill patients treated with high flow nasal cannula oxygen: a prospective observational multicenter study
Authors' conclusion
HFNC during intra-hospital transport of critically ill patients had a low incidence of severe adverse events.
Study context
- Population
- Critically ill adults treated with HFNC before transport who required intra-hospital transport accompanied by an ICU team, May 2022–May 2024187 transports analysed
- Participants
- 165 adults
- Outcome
- Incidence of severe adverse events (severe hypoxemia [SpO2 <80%], need for intubation, need for NIV or cardiorespiratory arrest) during transport
Methodological detailsdescriptive, multicentre
- Descriptive
- Multicentre
Main finding
As reported in the abstract
Severe adverse events during transport
Severe adverse events (in 7 patients)
8
4.3%
Severe transient hypoxemia
6
NIV
2
Observational data: associations, not effects.
Secondary outcomes
- Non-severe adverse events
- 43 (23%)
- Increased FiO2 requirement
- 29 (15.6%)
- Nasal cannula removal
- 7/187 (3.74%)
- HFNC device dysfunction
- 6/187 (3.2%)
- HFNC replaced with standard oxygen therapy
- 1 (0.5%)
Original publication
Intra-hospital transport of adult critically ill patients treated with high flow nasal cannula oxygen: a prospective observational multicenter study. Ann Intensive Care. Published 8 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →